Its current indications include the identification of BRCA1 and BRCA2 mutations in patients affected by ovarian cancer potentially eligible for rucaparib, the detection of ALK rearrangements in patients affected by NSCLC potentially eligible for alectinib, the detection of PIK3CA mutations in patients affected by breast cancer potentially eligible for alpelisib and the detection of BRCA1, BRCA2 and ATM mutations in patients affected by castration-resistant prostate cancer who can beneficiate from treatment with olaparib. This evidence concerns the gene BRCA2 and prostate cancer.